» Articles » PMID: 33686242

LIMK1 Nuclear Translocation Promotes Hepatocellular Carcinoma Progression by Increasing P-ERK Nuclear Shuttling and by Activating C-Myc Signalling Upon EGF Stimulation

Overview
Journal Oncogene
Date 2021 Mar 9
PMID 33686242
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

LIM kinase 1 (LIMK1) is a serine/threonine and tyrosine kinase that is predominantly located in the cytoplasm. In our study, nuclear translocation of LIMK1 in clinical hepatocellular carcinoma (HCC) samples was demonstrated for the first time, especially in samples from those with intravascular tumour thrombus. LIMK1 was overexpressed in HCC tissues, and nuclear LIMK1 expression was associated with poor prognosis in HCC patients. Although the effects of cytoplasmic LIMK1 on cofilin phosphorylation and actin filament dynamics have been well studied, the function of nuclear LIMK1 is still unclear. Gain- and loss-of-function experiments were performed both in vitro and in vivo and demonstrated a correlation between nuclear LIMK1 and the enhanced aggressive phenotype of HCC. EGF could drive the nuclear translocation of LIMK1 by activating the interaction of p-ERK and LIMK1 and facilitating their roles in nuclear shuttling. Moreover, nuclear LIMK1 could directly bind to the promoter region of c-Myc and stimulate c-Myc transcription. Although the EGFR monoclonal antibody cetuximab has a poor therapeutic effect on advanced HCC patients, in vivo animal study showed that cetuximab achieved a significant inhibitory effect on the progression of nuclear LIMK1-overexpressing HCC cells. In addition, recent data have demonstrated the potential of cetuximab in combination therapy for HCC patients with LIMK1 nuclear translocation.

Citing Articles

PDZ and LIM Domain-Encoding Genes: Their Role in Cancer Development.

Jiang X, Xu Z, Jiang S, Wang H, Xiao M, Shi Y Cancers (Basel). 2023; 15(20).

PMID: 37894409 PMC: 10605254. DOI: 10.3390/cancers15205042.


Exploring potential targets of Actinidia chinensis Planch root against hepatocellular carcinoma based on network pharmacology and molecular docking and development and verification of immune-associated prognosis features for hepatocellular carcinoma.

Qu M, Han T, Chen X, Sun Q, Li Q, Zhao M J Gastrointest Oncol. 2022; 13(3):1289-1307.

PMID: 35837167 PMC: 9274039. DOI: 10.21037/jgo-22-398.


Identification of novel lipid biomarkers in xmrk- and Myc-induced models of hepatocellular carcinoma in zebrafish.

Monroe J, Fraher D, Huang X, Mellett N, Meikle P, Sinclair A Cancer Metab. 2022; 10(1):7.

PMID: 35379333 PMC: 8981695. DOI: 10.1186/s40170-022-00283-y.


Protein domain-based prediction of drug/compound-target interactions and experimental validation on LIM kinases.

Dogan T, Akhan Guzelcan E, Baumann M, Koyas A, Atas H, Baxendale I PLoS Comput Biol. 2021; 17(11):e1009171.

PMID: 34843456 PMC: 8659301. DOI: 10.1371/journal.pcbi.1009171.


MMP9 Differentially Regulates Proteins Involved in Actin Polymerization and Cell Migration during TGF-β-Induced EMT in the Lens.

Liu Z, Taiyab A, West-Mays J Int J Mol Sci. 2021; 22(21).

PMID: 34769418 PMC: 8584335. DOI: 10.3390/ijms222111988.


References
1.
Buonaguro L, Petrizzo A, Tagliamonte M, Tornesello M, Buonaguro F . Challenges in cancer vaccine development for hepatocellular carcinoma. J Hepatol. 2013; 59(4):897-903. DOI: 10.1016/j.jhep.2013.05.031. View

2.
Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

3.
Llovet J, Burroughs A, Bruix J . Hepatocellular carcinoma. Lancet. 2003; 362(9399):1907-17. DOI: 10.1016/S0140-6736(03)14964-1. View

4.
Kim E, Kim D, Lee J, Yoe J, Park J, Kim C . Capicua suppresses hepatocellular carcinoma progression by controlling the ETV4-MMP1 axis. Hepatology. 2017; 67(6):2287-2301. DOI: 10.1002/hep.29738. View

5.
Craig A, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A . Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2019; 17(3):139-152. DOI: 10.1038/s41575-019-0229-4. View